The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
Enhanced half‐life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.
487-498
Collins, P.
f9aca28f-9bc3-45b8-aa5b-b36c974c94c6
Chalmers, E.
af5bb068-8312-47a5-8842-48b82e3a9787
Chowdary, P.
486dd610-f471-49ab-b999-c2145bdd62c3
Keeling, D.
113e2f8d-9051-4312-9d7c-0f147e237d2b
Mathias, M.
1fd987a0-a6b4-45d4-b992-4282e6b51555
O'donnell, J.
10102a79-e385-4506-9631-f543ba7dd41a
Pasi, K. J.
3b81e0be-6e79-4b71-95c5-45fe04b8e6dc
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Thomas, A.
56ca65f4-0761-442d-9266-d87443ef40fe
1 July 2016
Collins, P.
f9aca28f-9bc3-45b8-aa5b-b36c974c94c6
Chalmers, E.
af5bb068-8312-47a5-8842-48b82e3a9787
Chowdary, P.
486dd610-f471-49ab-b999-c2145bdd62c3
Keeling, D.
113e2f8d-9051-4312-9d7c-0f147e237d2b
Mathias, M.
1fd987a0-a6b4-45d4-b992-4282e6b51555
O'donnell, J.
10102a79-e385-4506-9631-f543ba7dd41a
Pasi, K. J.
3b81e0be-6e79-4b71-95c5-45fe04b8e6dc
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Thomas, A.
56ca65f4-0761-442d-9266-d87443ef40fe
Collins, P., Chalmers, E., Chowdary, P., Keeling, D., Mathias, M., O'donnell, J., Pasi, K. J., Rangarajan, S. and Thomas, A.
(2016)
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Haemophilia, 22 (4), .
(doi:10.1111/hae.13013).
Abstract
Enhanced half‐life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.
This record has no associated files available for download.
More information
Accepted/In Press date: 12 May 2016
e-pub ahead of print date: 16 June 2016
Published date: 1 July 2016
Identifiers
Local EPrints ID: 442890
URI: http://eprints.soton.ac.uk/id/eprint/442890
ISSN: 1351-8216
PURE UUID: 324928ad-d46c-4df2-ae5f-11b125223abc
Catalogue record
Date deposited: 30 Jul 2020 16:31
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
P. Collins
Author:
E. Chalmers
Author:
P. Chowdary
Author:
D. Keeling
Author:
M. Mathias
Author:
J. O'donnell
Author:
K. J. Pasi
Author:
A. Thomas
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
